Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.62 |
| ▸ | MAOB | P27338 | 11/20 | 0.62 |
| ▸ | TOP1 | P11387 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351678 | 1.00 | MAOA (0.62) | MAOAMAOBTOP1TNKS2CREBBP | |
| SCHEMBL6351016 | 0.78 | NTRK1 (0.46) | MAOAMAOB | |
| SCHEMBL6351020 | 0.78 | NTRK1 (0.46) | MAOAMAOB | |
| SCHEMBL9728150 | 0.78 | MAOB (1.00) | MAOAMAOBTOP1GSTP1 | |
| SCHEMBL6353252 | 0.76 | PTPN7 (0.42) | MAOAMAOBL3MBTL1 | |
| SCHEMBL6353249 | 0.76 | PTPN7 (0.42) | MAOAMAOBL3MBTL1 | |
| SCHEMBL6279537 | 0.76 | MAPT (0.50) | MAOAMAOBL3MBTL1 | |
| SCHEMBL6358112 | 0.76 | MAPT (0.50) | MAOAMAOBL3MBTL1 | |
| SCHEMBL6354675 | 0.75 | MDM2 (0.40) | MAOAMAOB | |
| SCHEMBL6354674 | 0.75 | MDM2 (0.40) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | MAOA 4445/4885MAOB 4555/4885TOP1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.